Dr. Arrowsmith received her PhD from the University of Toronto in 1987 and post-doctoral training at Stanford University. In 1991 she started her independent research program at the Ontario Cancer Institute investigating how transcription factors recognize DNA to regulate gene expression and cell growth.
- Epigenetics and Drug DiscoveryEpigenetics refers to heritable differences in phenotype that are due to mechanisms other than differences in DNA sequence. Epigenetics involves a dynamic interplay between DNA methylation, posttranslational modification of histones and other proteins, and noncoding RNA networks that control gene expression programs in normal and diseased cells.
Mutations in chromatin regulatory genes and alterations of the cellular epigenome are prevalent in most cancers. Post-translational modifications (PTMs) on histone proteins serve as docking sites for chromatin-associated proteins, which in turn dictate dynamic conversion between transcriptionally active or silent chromatin states. The combinatorial nature of these modifications establishes a "histone code" which serves to expand the information present in the DNA-sequence of the genetic code. Lysine methylation is the most complex mark, and it plays a pivotal role in heterochromatin formation, transcriptional regulation and X-chromosome inactivation. Mutations or aberrant expression of proteins containing these domains often leads to deregulation of histone lysine methylation, leading to various diseases, most notably, cancer.
We work with the Structural Genomics Consortium (SGC) to develop structure-based potent, selective, cell-active small molecule inhibitors of individual epigenetic regulatory proteins. These compounds, also referred to as chemical probes, are extremely valuable for understanding epigenetic signaling mechanisms in cells. Chemical probes are highly complementary to genetic methods and more closely mimic strategies for therapeutic translation. We are providing our epigenetic chemical probes as an Open Access resource to the biological research community to facilitate understanding of epigenetic mechanisms and to more rapidly identify and validate therapeutic targets for cancer and other diseases.
- p53, ubiquitin signaling, and cancerp53 protein plays a major role in maintaining the integrity of the genome. One of its major roles in normal cells is the induction of cell cycle arrest or apoptosis in response DNA damage, by activating or repressing transcription of genes involved in these processes. Inactivation of the tumor suppressor p53 through deletion, mutation or interaction with proteins is a key step in over half of all human cancers. We are particularly interested in understanding, at the atomic levels, how various cellular proteins interact with and regulate the function of p53. Some of the proteins we have characterized include Replication Protein A (RPA), Ubiquitin Specific Protease 7 (USP7), Cullin 7 (Cul7) and Pirh2. Results from these studies have provided insight into the molecular mechanism of p53 regulation via protein-protein and protein-peptide interactions.
Our work on ubiquitin-mediated regulation of p53 has led us to wider consideration of ubuquitylation pathways. Again in collaboration with the SGC we have studied proteins involved in chromatin ubiquitylation (UHRF1, UHRF2, Ring1b) and the entire E2 ubiquitin ligase and ubiquitin-like domain families.
- NMR spectroscopy and hybrid methods in structural biologyNMR spectroscopy and x-ray crystallography are the two common techniques used to determine the structure of proteins. We have developed NMR analysis resources such as ABACUS, a protocol that analyzes networks of J-correlated spectral peptide-linked peaks and NOE spectral peaks combined with a fragment monte carlo (FMC) procedure to sequence-specifically assign the backbone and side-chain resonances of proteins. To date, this method had been used to solve over 85 protein structures deposited in the PDB. The ABACUS protocol is available for download here.
We also employ x-ray crystallography, small angle X-ray scattering (SAXS) and chemical crosslinking as tools to characterize multidomain proteins and multiprotein complexes with hybrid computational strategies.
Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
J Med Chem. 2016 Jul 28;
Methods Enzymol. 2016;574:79-103
Discovery of a Potent and Selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) Inhibitor by Virtual Screening.
J Med Chem. 2016 Jul 8;
Nat Chem Biol. 2016 Mar;12(3):180-7
Curr Opin Chem Biol. 2016 Jun 16;33:81-87
Nat Struct Mol Biol. 2016 Jun 13;
J Proteome Res. 2016 May 10;
J Biol Chem. 2016 Apr 29;
Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.
J Med Chem. 2016 Apr 13;
SETD7 Controls Intestinal Regeneration and Tumorigenesis by Regulating Wnt/β-Catenin and Hippo/YAP Signaling.
Dev Cell. 2016 Apr 4;37(1):47-57
Senior Scientist, Princess Margaret Cancer Centre
Professor, Department of Medical Biophysics, Faculty of Medicine, University of Toronto
Chief Scientist, Structural Genomics Consortium, Toronto